Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care

Published:2018-06 Issue:S2 Volume:20 Page:S2-69-S2-77
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Danne Thomas¹,Biester Torben¹,Kordonouri Olga¹

Affiliation:

1. Diabetes Center for Children and Adolescents Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2018.0081

Reference49 articles.

1. Phlorizin: a review

2. THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN

3. LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

4. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

5. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes;ESC Heart Failure;2024-09-10

2. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin;Clinical Pharmacology & Therapeutics;2024-03-08

3. A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus;European Journal of Pharmaceutical Sciences;2024-01

4. A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old;Cureus;2023-09-13

5. New therapies towards a better glycemic control in youths with type 1 diabetes;Pharmacological Research;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3